American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Vigil Neuroscience (NASDAQ:VIGL) Receives Buy Rating from HC Wainwright

Vigil Neuroscience (NASDAQ:VIGL) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a $24.00 price target on the stock. Separately,... More of this article »
Image about Virtus Investment Partners (NASDAQ:VRTS) Price Target Increased to $275.00 by Analysts at Piper Sandler

Virtus Investment Partners (NASDAQ:VRTS) Price Target Increased to $275.00 by Analysts at Piper Sandler

Virtus Investment Partners (NASDAQ:VRTS – Free Report) had its price objective hoisted by Piper Sandler from $264.00 to $275.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an... More of this article »
Image about ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Lowered to $18.00 at JPMorgan Chase & Co.

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Lowered to $18.00 at JPMorgan Chase & Co.

ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $19.00 to $18.00 in a report published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently... More of this article »
Image about Marvell Technology (NASDAQ:MRVL) Given Buy Rating at Citigroup

Marvell Technology (NASDAQ:MRVL) Given Buy Rating at Citigroup

Citigroup restated their buy rating on shares of Marvell Technology (NASDAQ:MRVL – Free Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $91.00 target price on the semiconductor... More of this article »
Image about Sanara MedTech (NASDAQ:SMTI) Given New $44.00 Price Target at Cantor Fitzgerald

Sanara MedTech (NASDAQ:SMTI) Given New $44.00 Price Target at Cantor Fitzgerald

Sanara MedTech (NASDAQ:SMTI – Free Report) had its price target trimmed by Cantor Fitzgerald from $49.00 to $44.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an overweight... More of this article »
Image about PaySign (NASDAQ:PAYS) Receives Outperform Rating from Barrington Research

PaySign (NASDAQ:PAYS) Receives Outperform Rating from Barrington Research

Barrington Research reaffirmed their outperform rating on shares of PaySign (NASDAQ:PAYS – Free Report) in a research note released on Wednesday, Benzinga reports. They currently have a $5.50 price target on the stock. Other... More of this article »
Image about RAPT Therapeutics (NASDAQ:RAPT) Given New $13.00 Price Target at JPMorgan Chase & Co.

RAPT Therapeutics (NASDAQ:RAPT) Given New $13.00 Price Target at JPMorgan Chase & Co.

RAPT Therapeutics (NASDAQ:RAPT – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $15.00 to $13.00 in a research report released on Wednesday, Benzinga reports. The firm currently has a neutral rating... More of this article »
Image about Sigma Lithium (NASDAQ:SGML) Price Target Lowered to $30.00 at BMO Capital Markets

Sigma Lithium (NASDAQ:SGML) Price Target Lowered to $30.00 at BMO Capital Markets

Sigma Lithium (NASDAQ:SGML – Free Report) had its price objective decreased by BMO Capital Markets from $38.00 to $30.00 in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. BMO Capital Markets... More of this article »
Image about PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $21.00 target price on... More of this article »
Image about Shockwave Medical (NASDAQ:SWAV) Now Covered by Analysts at CL King

Shockwave Medical (NASDAQ:SWAV) Now Covered by Analysts at CL King

CL King started coverage on shares of Shockwave Medical (NASDAQ:SWAV – Free Report) in a research note issued to investors on Wednesday, MarketBeat reports. The firm issued a buy rating and a $368.00 target price on the stock. Other... More of this article »
Image about argenx (NASDAQ:ARGX) Given Buy Rating at HC Wainwright

argenx (NASDAQ:ARGX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of argenx (NASDAQ:ARGX – Free Report) in a research note released on Wednesday, Benzinga reports. The firm currently has a $451.00 price objective on the stock. A number of... More of this article »
Image about American Battery Technology (NASDAQ:ABAT) Receives New Coverage from Analysts at Northland Securities

American Battery Technology (NASDAQ:ABAT) Receives New Coverage from Analysts at Northland Securities

Northland Securities started coverage on shares of American Battery Technology (NASDAQ:ABAT – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating... More of this article »
Image about Match Group’s (MTCH) Overweight Rating Reaffirmed at Piper Sandler

Match Group’s (MTCH) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler restated their overweight rating on shares of Match Group (NASDAQ:MTCH – Free Report) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $45.00 price objective on the technology... More of this article »
Image about Bitdeer Technologies Group’s (BTDR) Buy Rating Reaffirmed at Benchmark

Bitdeer Technologies Group’s (BTDR) Buy Rating Reaffirmed at Benchmark

Benchmark reissued their buy rating on shares of Bitdeer Technologies Group (NASDAQ:BTDR – Free Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $13.00 price target on the stock. Several... More of this article »
Image about Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Outperform” Rating from BMO Capital Markets

Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives “Outperform” Rating from BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $234.00 price objective on the biopharmaceutical... More of this article »